Abstract
Our current thoracic oncology practice could/should be adapted to the COVID-19 pandemic by reducing time in hospital and patient contacts with healthcare workers, whilst maintaining quality of care. This letter offers expert advice on how to do so. https://bit.ly/2JR2IoT
MeSH terms
-
Belgium
-
COVID-19
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / radiotherapy
-
Carcinoma, Non-Small-Cell Lung / surgery
-
Coronavirus Infections / epidemiology*
-
Disease Susceptibility
-
France
-
Humans
-
Lung Neoplasms / drug therapy
-
Mesothelioma / drug therapy
-
Mesothelioma, Malignant
-
Neoplasms / drug therapy
-
Neoplasms / radiotherapy
-
Neoplasms / surgery
-
Neoplasms / therapy*
-
Neoplasms, Glandular and Epithelial / drug therapy
-
Pandemics
-
Pneumonia, Viral / epidemiology*
-
Practice Guidelines as Topic
-
Prognosis
-
Small Cell Lung Carcinoma / drug therapy
-
Small Cell Lung Carcinoma / radiotherapy
-
Societies, Medical
-
Telemedicine
-
Thymus Neoplasms / drug therapy
-
United Kingdom
-
Videoconferencing